Literature DB >> 23509992

Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases.

Arpad Ivanecz1, Rajko Kavalar, Miroslav Palfy, Vid Pivec, Marko Sremec, Matjaž Horvat, Stojan Potrč.   

Abstract

OBJECTIVES: The aim of this study was to assess whether biological markers can provide prognostic information additional to that supplied by the clinical risk score (CRS) in patients with colorectal liver metastases.
METHODS: A retrospective review of a prospectively maintained database was conducted. Patients selected for this study were treated between 1996 and 2011 with potentially curative liver surgery. Expressions of p53, Ki-67 and thymidylate synthase were assayed using immunohistochemical techniques on tissue microarrays.
RESULTS: A total of 98 (24%) of 406 patients met the inclusion criteria. The median follow-up was 103 months. Analysis revealed a correlation between p53 protein overexpression and high CRS (P = 0.058). Following multivariate analysis, only high CRS remained as an independent negative prognostic predictor of survival (P = 0.018), as well as an indicator of early recurrence of disease (P = 0.010). Of the biological markers investigated, only Ki-67 overexpression was identified as a positive predictor of survival on multivariate analysis (P = 0.038).
CONCLUSIONS: Ki-67 overexpression was a positive predictor of survival. Only high CRS remained an independent negative prognostic predictor.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509992      PMCID: PMC3945849          DOI: 10.1111/hpb.12089

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  39 in total

1.  Tissue microarrays: a new approach for quality control in immunohistochemistry.

Authors:  J Packeisen; H Buerger; R Krech; W Boecker
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

2.  Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.

Authors:  H Petrowsky; I Sturm; O Graubitz; D A Kooby; E Staib-Sebler; C Gog; C H Köhne; T Hillebrand; P T Daniel; Y Fong; M Lorenz
Journal:  Eur J Surg Oncol       Date:  2001-02       Impact factor: 4.424

3.  P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.

Authors:  Y Yang; A Forslund; H Remotti; C Lönnroth; M Andersson; H Brevinge; E Svanberg; P Lindnér; L Hafström; P Naredi; K Lundholm
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

4.  Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer.

Authors:  P J Crowe; J L Yang; C R Berney; C Erskine; J M Ham; R Fisher; P J Russell
Journal:  World J Surg       Date:  2001-08       Impact factor: 3.352

5.  Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.

Authors:  D C Corsi; M Ciaparrone; G Zannoni; M Mancini; A Cassano; M Specchia; C Pozzo; M Martini; C Barone
Journal:  Eur J Cancer       Date:  2002-03       Impact factor: 9.162

6.  Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases.

Authors:  H H J Backus; C J Van Groeningen; W Vos; D F Dukers; E Bloemena; D Wouters; H M Pinedo; G J Peters
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

7.  Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.

Authors:  Mithat Gonen; Amanda Hummer; Alice Zervoudakis; Deidre Sullivan; Yuman Fong; Debabrata Banerjee; David Klimstra; Carlos Cordon-Cardo; Joseph Bertino; Nancy Kemeny
Journal:  J Clin Oncol       Date:  2003-02-01       Impact factor: 44.544

8.  p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.

Authors:  R P M Saw; D Koorey; D Painter; P J Gallagher; M J Solomon
Journal:  Br J Surg       Date:  2002-11       Impact factor: 6.939

9.  Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases.

Authors:  David L Smith; Jean-Charles Soria; Luc Morat; Qinghua Yang; Laure Sabatier; Diane D Liu; Rabih A Nemr; Asif Rashid; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2004-01       Impact factor: 5.344

10.  Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

Authors:  Marie-Christine Etienne; Maurice Chazal; Pierre Laurent-Puig; Nicolas Magné; Christophe Rosty; Jean-Louis Formento; Mireille Francoual; Patricia Formento; Nicole Renée; Emmanuel Chamorey; André Bourgeon; Jean-François Seitz; Jean-Robert Delpero; Christian Letoublon; Denis Pezet; Gérard Milano
Journal:  J Clin Oncol       Date:  2002-06-15       Impact factor: 44.544

View more
  10 in total

Review 1.  Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.

Authors:  Sean M Ronnekleiv-Kelly; Richard A Burkhart; Timothy M Pawlik
Journal:  Surg Oncol       Date:  2016-05-20       Impact factor: 3.279

Review 2.  Surgery for colorectal liver metastases: The evolution of determining prognosis.

Authors:  Gaya Spolverato; Aslam Ejaz; Nilo Azad; Timothy M Pawlik
Journal:  World J Gastrointest Oncol       Date:  2013-12-15

Review 3.  Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?

Authors:  Carlotta Barbon; Georgios Antonios Margonis; Nikolaos Andreatos; Neda Rezaee; Kazunari Sasaki; Stefan Buettner; Christos Damaskos; Timothy M Pawlik; Jin He; Christopher L Wolfgang; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2018-04-11       Impact factor: 3.452

4.  Simultaneous Pure Laparoscopic Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: A Single Institution Experience with Propensity Score Matching Analysis.

Authors:  Arpad Ivanecz; Bojan Krebs; Andraz Stozer; Tomaz Jagric; Irena Plahuta; Stojan Potrc
Journal:  Radiol Oncol       Date:  2017-11-01       Impact factor: 2.991

5.  Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis.

Authors:  Zhao-Wen Luo; Ming-Gu Zhu; Zhi-Qiao Zhang; Feng-Jun Ye; Wen-Heng Huang; Xue-Zhang Luo
Journal:  BMC Cancer       Date:  2019-02-06       Impact factor: 4.430

6.  Efficacy and safety of short duration radiotherapy combined with chemotherapy for advanced rectal cancer.

Authors:  Shu-Quan Gao; Ying-Chun Zhang; Chao Zhang; Sheng-Jie Wang; Wei Ren; Na Yuan; Jun-Ye Wen
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

7.  Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy.

Authors:  Wen-Juan Ma; Yukun Chen; Jian-Hong Peng; Chaoming Tang; Ling Zhang; Min Liu; Shanshan Hu; Haineng Xu; Hua Tan; Yangkui Gu; Zhi-Zhong Pan; Gong Chen; Zhong-Guo Zhou; Rong-Xin Zhang
Journal:  Cell Death Dis       Date:  2022-05-06       Impact factor: 9.685

Review 8.  Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis.

Authors:  William Torén; Daniel Ansari; Roland Andersson
Journal:  Cancer Cell Int       Date:  2018-12-27       Impact factor: 5.722

Review 9.  Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

Authors:  Markus K Diener; Stefan Fichtner-Feigl
Journal:  Ann Gastroenterol Surg       Date:  2021-07-06

10.  Clinical Significance and Prognostic Value of the Maximum Standardized Uptake Value of 18F-Flurodeoxyglucose Positron Emission Tomography-Computed Tomography in Colorectal Cancer.

Authors:  Yi-Xin Yin; Ming-Zhi Xie; Xin-Qiang Liang; Meng-Ling Ye; Ji-Lin Li; Bang-Li Hu
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.